URMC / Research / Clinical Trials / Study Details IGIH19161, Hezel, NuTide:121, Hepatoboliary, NUC-1031 Research Question:NuTide:121 compares NUC-1031 with gemcitabine, both in combination with cisplatin, in patients with previously untreated advanced biliary tract cancer.Basic Study Information Purpose:NuTide:121 compares NUC-1031 with gemcitabine, both in combination with cisplatin, in patients with previously untreated advanced biliary tract cancer. The primary hypotheses are: The combination of NUC-1031 plus cisplatin prolongs overall survival compared to the gemcitabine plus cisplatin standard of care The combination of NUC-1031 plus cisplatin increases overall response rate compared to the gemcitabine plus cisplatin standard of care Location: University of Rochester Medical CenterStudy Reference #: IGIH19161Lead Researcher (Principal Investigator) Lead Researcher: Aram Hezel Study Contact InformationStudy Coordinator: Tina BowdishPhone: +1 585-275-9475Email: tina_bowdish@urmc.rochester.edu Additional Study Details URMC / Wilmot Cancer Institute /Research / Clinical Trials / Study Details Trial Not Found The study you are looking for is not active at this time. Return to Search